Search Results

Deals

Harmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals and Expands Pipeline

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc.

October 11, 2023

·

8 min read

Deals

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc.

August 14, 2023

·

13 min read

Pharm Country

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Zynerba Pharmaceuticals, Inc. announced that the new date for the adjourned 2023 Annual Meeting of Stockholders is August 11, 2023 at 9:00 a.m. EDT.

July 25, 2023

·

4 min read

Pictured: Businessmen shaking hands after closing a deal

Deals

Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout

Following its Scorpion Capital controversy in March, Harmony Biosciences is seeking to deepen its pipeline with an acquisition of Zynerba Pharmaceuticals’ cannabinoid therapies for neuropsychiatric disorders.

August 15, 2023

·

2 min read

·

Tristan Manalac

Pharm Country

Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting

Zynerba Pharmaceuticals, Inc. announced that it has adjourned its 2023 Annual Meeting of Stockholders solely with respect to Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 21, 2023.

June 13, 2023

·

4 min read

Pharm Country

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”).

September 29, 2023

·

15 min read

Pharm Country

Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40 p.m. ET, and host investor meetings.

March 7, 2023

·

4 min read

Pharm Country

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium.

September 14, 2023

·

6 min read

Business

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2023, and provided an overview of recent operational highlights and a pipeline update.

May 15, 2023

·

12 min read

Pharm Country

Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, is presenting two posters at the 55th Gatlinburg Conference, being held April 10-13, 2023, in Kansas City, Mo.

April 12, 2023

·

7 min read